Company intelligence / Profile preview

Alvaxa Biosciences

Seattle, Washington, United States

Ownership: Private
Development stage: Other

Overview

Alvaxa Biosciences was acquired by Sensei Biotherapeutics before advancing any programs into clinical development. The company's camelid nanobody platform was integrated into Sensei's ImmunoPhage platform.

Modalities: Nanobody therapyMonoclonal antibody
Industry: Biotech

Partnerships

Fred Hutchinson Cancer Research CenterHope Farms

Beyond the preview

Go deeper on Alvaxa Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alvaxa Biosciences.

Explore the full profile